Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review

Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery. From the NAC response, it is possible to obtain prognostic information as patients may reach a pathological complete response (pCR). Those wh...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 13; no. 21; p. 5477
Main Authors Freitas, Ana Julia Aguiar de, Causin, Rhafaela Lima, Varuzza, Muriele Bertagna, Hidalgo Filho, Cassio Murilo Trovo, Silva, Vinicius Duval da, Souza, Cristiano de Pádua, Marques, Márcia Maria Chiquitelli
Format Journal Article
LanguageEnglish
Published Basel MDPI AG 31.10.2021
MDPI
Subjects
Biomarkers
Breast cancer
Chemotherapy
DNA methylation
Genomics
Mutation
Patients
Precision medicine
Proteomics
Review
Transcriptomics
Tumors
Online AccessGet full text

Cover

Abstract Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery. From the NAC response, it is possible to obtain prognostic information as patients may reach a pathological complete response (pCR). Those who do might have significant advantages in terms of survival rates. Breast cancer (BC) is a heterogeneous disease that requires personalized treatment strategies. The development of targeted therapies depends on identifying biomarkers that can be used to assess treatment efficacy as well as the discovery of new and more accurate therapeutic agents. With the development of new “OMICS” technologies, i.e., genomics, transcriptomics, and proteomics, among others, the discovery of new biomarkers is increasingly being used in the context of clinical practice, bringing us closer to personalized management of BC treatment. The aim of this review is to compile the main biomarkers that predict pCR in BC after NAC.
AbstractList Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery. From the NAC response, it is possible to obtain prognostic information as patients may reach a pathological complete response (pCR). Those who do might have significant advantages in terms of survival rates. Breast cancer (BC) is a heterogeneous disease that requires personalized treatment strategies. The development of targeted therapies depends on identifying biomarkers that can be used to assess treatment efficacy as well as the discovery of new and more accurate therapeutic agents. With the development of new “OMICS” technologies, i.e., genomics, transcriptomics, and proteomics, among others, the discovery of new biomarkers is increasingly being used in the context of clinical practice, bringing us closer to personalized management of BC treatment. The aim of this review is to compile the main biomarkers that predict pCR in BC after NAC.
Simple SummaryBreast cancer is the most common cancer in women worldwide. Although many studies have aimed to understand the genetic basis of breast cancer, leading to increasingly accurate diagnoses, only a few molecular biomarkers are used in clinical practice to predict response to therapy. Current studies aim to develop more personalized therapies to decrease the adverse effects of chemotherapy. Personalized medicine not only requires clinical, but also molecular characterization of tumors, which allows the use of more effective drugs for each patient. The aim of this study was to identify potential molecular biomarkers that can predict the response to therapy after neoadjuvant chemotherapy in patients with breast cancer. In this review, we summarize genomic, transcriptomic, and proteomic biomarkers that can help predict the response to therapy.AbstractNeoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery. From the NAC response, it is possible to obtain prognostic information as patients may reach a pathological complete response (pCR). Those who do might have significant advantages in terms of survival rates. Breast cancer (BC) is a heterogeneous disease that requires personalized treatment strategies. The development of targeted therapies depends on identifying biomarkers that can be used to assess treatment efficacy as well as the discovery of new and more accurate therapeutic agents. With the development of new “OMICS” technologies, i.e., genomics, transcriptomics, and proteomics, among others, the discovery of new biomarkers is increasingly being used in the context of clinical practice, bringing us closer to personalized management of BC treatment. The aim of this review is to compile the main biomarkers that predict pCR in BC after NAC.
Author Silva, Vinicius Duval da
Souza, Cristiano de Pádua
Causin, Rhafaela Lima
Varuzza, Muriele Bertagna
Freitas, Ana Julia Aguiar de
Marques, Márcia Maria Chiquitelli
Hidalgo Filho, Cassio Murilo Trovo
AuthorAffiliation 4 Barretos School of Health Sciences, Dr. Paulo Prata–FACISB, Barretos 14785-002, SP, Brazil
1 Molecular Oncology Research Center, Barretos Cancer Hospital, Teaching and Research Institute, Barretos 14784-400, SP, Brazil; aaguiardefreitas@gmail.com (A.J.A.d.F.); rhafaela-lima@hotmail.com (R.L.C.); mbertagnav@gmail.com (M.B.V.)
3 Barretos Cancer Hospital, Barretos 14784-400, SP, Brazil; vinids@gmail.com (V.D.d.S.); crispadua10@gmail.com (C.d.P.S.)
2 Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo 01246-000, SP, Brazil; cmtrovohidalgo@gmail.com
AuthorAffiliation_xml – name: 3 Barretos Cancer Hospital, Barretos 14784-400, SP, Brazil; vinids@gmail.com (V.D.d.S.); crispadua10@gmail.com (C.d.P.S.)
– name: 2 Instituto do Câncer do Estado de São Paulo (ICESP), São Paulo 01246-000, SP, Brazil; cmtrovohidalgo@gmail.com
– name: 4 Barretos School of Health Sciences, Dr. Paulo Prata–FACISB, Barretos 14785-002, SP, Brazil
– name: 1 Molecular Oncology Research Center, Barretos Cancer Hospital, Teaching and Research Institute, Barretos 14784-400, SP, Brazil; aaguiardefreitas@gmail.com (A.J.A.d.F.); rhafaela-lima@hotmail.com (R.L.C.); mbertagnav@gmail.com (M.B.V.)
Author_xml – sequence: 1
  givenname: Ana Julia Aguiar de
  orcidid: 0000-0002-9677-2093
  surname: Freitas
  fullname: Freitas, Ana Julia Aguiar de
– sequence: 2
  givenname: Rhafaela Lima
  orcidid: 0000-0003-1749-9736
  surname: Causin
  fullname: Causin, Rhafaela Lima
– sequence: 3
  givenname: Muriele Bertagna
  orcidid: 0000-0002-4482-6440
  surname: Varuzza
  fullname: Varuzza, Muriele Bertagna
– sequence: 4
  givenname: Cassio Murilo Trovo
  orcidid: 0000-0002-7046-0059
  surname: Hidalgo Filho
  fullname: Hidalgo Filho, Cassio Murilo Trovo
– sequence: 5
  givenname: Vinicius Duval da
  orcidid: 0000-0003-3515-0263
  surname: Silva
  fullname: Silva, Vinicius Duval da
– sequence: 6
  givenname: Cristiano de Pádua
  orcidid: 0000-0002-6412-8041
  surname: Souza
  fullname: Souza, Cristiano de Pádua
– sequence: 7
  givenname: Márcia Maria Chiquitelli
  orcidid: 0000-0001-5616-6710
  surname: Marques
  fullname: Marques, Márcia Maria Chiquitelli
BookMark eNpdkU1P3DAQhi1ExVc5c7XUSy8L_kqc9FCprFqoRFtUtWfLsSesF8cOdrJo_329gKoWX8ayn3n0juYY7YcYAKEzSs45b8mF0cFAypQzWgkp99ARI5It6roV-__cD9FpzmtSDudU1vIAHfKC01qQI7T9Fj2Y2euEL10cdLovRnybwDoz4Vs9raKPd85oj5dxGD1MgH9CHmPIgGOPv0PUdj1vdJjwcgVDnFaQ9LjFLuDLBDqX56eYO5eDMOUPpX_j4PEtetNrn-H0pZ6g318-_1peL25-XH1dfrpZGN420wI0JYxxK5m0vKGmJNdgu84KAj0RNXBhLQja970FMISwzladrbltQXLZ8xP08dk7zt0A1pQMSXs1Jlem3aqonfr_J7iVuosb1VQNqygtgvcvghQfZsiTGlw24L0OEOesWNVK0QpJmoK-e4Wu45xCGW9H1YQywdpCXTxTJsWcE_R_w1CidptVrzbL_wCl5Zu3
CitedBy_id crossref_primary_10_1016_j_tranon_2023_101782
crossref_primary_10_15407_exp_oncology_2023_01_120
crossref_primary_10_1016_j_yexmp_2024_104885
crossref_primary_10_1245_s10434_023_13233_9
crossref_primary_10_1016_j_esmoop_2022_100637
crossref_primary_10_3390_ijms24129984
crossref_primary_10_1097_CMR_0000000000000881
crossref_primary_10_3390_cancers15041317
crossref_primary_10_3390_cancers15010212
crossref_primary_10_1016_j_xcrm_2023_101312
crossref_primary_10_3390_ijms23179952
crossref_primary_10_2217_fon_2023_0886
Cites_doi 10.1016/j.heliyon.2020.e03241
10.1007/s12282-013-0474-2
10.1007/s10549-018-4801-3
10.1186/s13058-017-0806-9
10.1080/14789450.2018.1421071
10.2174/138920108785915102
10.4048/jbc.2013.16.4.395
10.1007/s10549-017-4132-9
10.1158/0008-5472.CAN-11-3711
10.1055/a-1124-7225
10.1186/s12916-018-1163-y
10.3390/cancers12082012
10.1016/j.annonc.2020.11.007
10.1007/s00280-019-03937-9
10.1126/scitranslmed.aax7392
10.1158/0008-5472.CAN-18-1079
10.1016/j.cancergen.2018.02.002
10.1038/nm.2305
10.1158/1078-0432.CCR-05-0735
10.1056/NEJMoa1602253
10.4143/crt.2019.497
10.1007/s12307-011-0064-9
10.1038/s41572-019-0111-2
10.1016/j.ejso.2019.08.001
10.1200/EDBK_320593
10.1186/gb-2004-5-4-219
10.1016/S0140-6736(16)32454-0
10.3390/ijms22020636
10.1158/1078-0432.CCR-18-2507
10.1155/2017/1750925
10.1158/1078-0432.CCR-10-1282
10.1200/JCO.2015.65.2289
10.1093/annonc/mdv161
10.1016/j.canlet.2005.11.027
10.1016/j.molonc.2010.11.003
10.1038/35021093
10.1007/s00280-011-1777-7
10.1158/2159-8290.CD-15-1483
10.1038/sj.bjc.6602787
10.1002/ijc.29985
10.1093/annonc/mdw434
10.1245/s10434-018-07107-8
10.1186/s12885-019-5403-0
10.1158/0008-5472.CAN-11-1630
10.3233/CBM-190523
10.1016/j.neo.2014.08.012
10.1007/s00280-019-03923-1
10.1200/JCO.2010.31.2231
10.1016/j.ejca.2011.06.014
10.1200/JCO.2007.10.6823
10.1080/14737159.2016.1184974
10.1186/s13046-018-0788-1
10.1016/j.ejca.2008.12.026
10.1016/j.ctrv.2018.04.012
10.1038/s41467-018-05228-y
10.1007/s10549-017-4503-2
10.18632/oncotarget.15118
10.1186/s12885-019-6353-2
10.1038/s41379-021-00738-5
10.1016/S0140-6736(13)62422-8
10.1158/0008-5472.CAN-05-1783
10.1158/1078-0432.CCR-11-0926
10.1186/bcr1018
10.1001/jamaoncol.2020.2535
10.1016/j.cub.2014.03.060
10.3390/cancers12051133
10.3390/ijms18020459
10.1038/sj.bjc.6600749
10.1016/j.ctrv.2013.07.006
10.1007/s10549-011-1412-7
10.1001/jamanetworkopen.2019.7700
10.1007/s10549-014-3079-3
10.1093/jnci/djr393
10.1200/JCO.2017.77.2285
10.1158/0008-5472.CAN-13-3392
10.1200/JCO.2011.38.8595
10.1155/2019/8393769
10.3390/ijms20174197
10.1038/341758a0
10.3322/caac.21492
10.3390/ijms21041386
10.1158/1078-0432.CCR-04-2421
10.1038/bjc.2011.145
10.1007/s11060-019-03358-x
10.1007/s10549-015-3435-y
10.1016/S1470-2045(09)70262-1
ContentType Journal Article
Copyright 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021 by the authors. 2021
Copyright_xml – notice: 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021 by the authors. 2021
DBID AAYXX
CITATION
3V.
7T5
7TO
7XB
8FE
8FH
8FK
8G5
ABUWG
AFKRA
AZQEC
BBNVY
BENPR
BHPHI
CCPQU
DWQXO
GNUQQ
GUQSH
H94
HCIFZ
LK8
M2O
M7P
MBDVC
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOI 10.3390/cancers13215477
DatabaseName CrossRef
ProQuest Central (Corporate)
Immunology Abstracts
Oncogenes and Growth Factors Abstracts
ProQuest Central (purchase pre-March 2016)
ProQuest SciTech Collection
ProQuest Natural Science Collection
ProQuest Central (Alumni) (purchase pre-March 2016)
Research Library (Alumni Edition)
ProQuest Central (Alumni)
ProQuest Central
ProQuest Central Essentials
Biological Science Collection
ProQuest Central
ProQuest Natural Science Collection
ProQuest One Community College
ProQuest Central
ProQuest Central Student
Research Library Prep
AIDS and Cancer Research Abstracts
SciTech Premium Collection (Proquest) (PQ_SDU_P3)
Biological Sciences
ProQuest research library
Biological Science Database
Research Library (Corporate)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DatabaseTitle CrossRef
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
Oncogenes and Growth Factors Abstracts
ProQuest Central Essentials
ProQuest Central (Alumni Edition)
SciTech Premium Collection
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Natural Science Collection
ProQuest Central China
ProQuest Central
Natural Science Collection
ProQuest Central Korea
Biological Science Collection
AIDS and Cancer Research Abstracts
ProQuest Research Library
ProQuest Biological Science Collection
ProQuest Central Basic
ProQuest One Academic Eastern Edition
Biological Science Database
ProQuest SciTech Collection
ProQuest One Academic UKI Edition
Immunology Abstracts
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef
Publicly Available Content Database
Database_xml – sequence: 1
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2072-6694
ExternalDocumentID 10_3390_cancers13215477
GroupedDBID ---
3V.
53G
5VS
8FE
8FH
8G5
AADQD
AAFWJ
AAYXX
ABDBF
ABUWG
ADBBV
AFKRA
AFPKN
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AOIJS
AZQEC
BAWUL
BBNVY
BCNDV
BENPR
BHPHI
BPHCQ
CCPQU
CITATION
DIK
DWQXO
E3Z
EBD
ESX
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HCIFZ
HYE
IAO
IHR
ITC
KQ8
LK8
M2O
M48
M7P
MODMG
M~E
OK1
P6G
PGMZT
PIMPY
PQQKQ
PROAC
RIG
RPM
TUS
7T5
7TO
7XB
8FK
H94
MBDVC
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
ID FETCH-LOGICAL-c398t-ea10223d727d381c477aedbbd40ef046e34dde41fffdeec002bd5bd63d9e737f3
IEDL.DBID RPM
ISSN 2072-6694
IngestDate Tue Sep 17 21:17:55 EDT 2024
Fri Oct 25 03:30:15 EDT 2024
Thu Oct 10 20:41:16 EDT 2024
Fri Aug 23 04:40:27 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 21
Language English
License Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c398t-ea10223d727d381c477aedbbd40ef046e34dde41fffdeec002bd5bd63d9e737f3
Notes ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
These authors contributed equally to this work and share first authorship.
ORCID 0000-0002-9677-2093
0000-0002-7046-0059
0000-0001-5616-6710
0000-0002-4482-6440
0000-0003-3515-0263
0000-0003-1749-9736
0000-0002-6412-8041
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8582511/
PMID 34771640
PQID 2596012429
PQPubID 2032421
ParticipantIDs pubmedcentral_primary_oai_pubmedcentral_nih_gov_8582511
proquest_miscellaneous_2597494708
proquest_journals_2596012429
crossref_primary_10_3390_cancers13215477
PublicationCentury 2000
PublicationDate 20211031
PublicationDateYYYYMMDD 2021-10-31
PublicationDate_xml – month: 10
  year: 2021
  text: 20211031
  day: 31
PublicationDecade 2020
PublicationPlace Basel
PublicationPlace_xml – name: Basel
PublicationTitle Cancers
PublicationYear 2021
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Shamai (ref_86) 2019; 2
Kong (ref_6) 2011; 47
Faneyte (ref_73) 2003; 88
Li (ref_3) 2005; 93
Fackler (ref_32) 2011; 71
Gasparello (ref_56) 2018; 37
Harbeck (ref_2) 2019; 5
Connolly (ref_31) 2018; 167
Filipits (ref_41) 2011; 17
Liefaard (ref_87) 2021; 41
ref_51
Beyene (ref_81) 2020; 6
Yerushalmi (ref_71) 2010; 11
Xing (ref_68) 2019; 84
Geiger (ref_61) 2012; 72
Gade (ref_55) 2014; 147
Esteller (ref_28) 2011; 17
Tibau (ref_26) 2014; 16
Cobleigh (ref_39) 2005; 11
Nakai (ref_69) 2012; 69
Katayama (ref_14) 2021; 34
Rouzier (ref_15) 2005; 11
Wood (ref_19) 2014; 40
Souza (ref_57) 2019; 2019
Goossens (ref_90) 2015; 4
Edenberg (ref_16) 2014; 24
Rohanizadegan (ref_35) 2018; 228–229
ref_25
Ma (ref_20) 2018; 9
Krawczyk (ref_17) 2020; 80
ref_66
Cerbelli (ref_67) 2017; 2017
Untch (ref_8) 2012; 30
Pease (ref_46) 2019; 26
Pantel (ref_58) 2016; 6
Cardoso (ref_40) 2016; 375
Mueller (ref_63) 2018; 15
Bray (ref_1) 2018; 68
Casey (ref_48) 2016; 139
ref_29
Cortazar (ref_82) 2014; 384
Huang (ref_34) 2006; 243
Yanovich (ref_62) 2018; 78
Lee (ref_74) 2013; 16
McCartney (ref_18) 2018; 67
Iorio (ref_47) 2005; 65
Fujii (ref_30) 2017; 8
Guan (ref_13) 2020; 28
Jerevall (ref_43) 2011; 104
Chuthapisith (ref_70) 2009; 45
Yamashita (ref_44) 2008; 9
Moss (ref_78) 2004; 5
ref_79
Harding (ref_76) 1989; 341
Cosimo (ref_52) 2019; 25
Haque (ref_88) 2018; 170
ref_75
Fackler (ref_33) 2014; 74
Prat (ref_4) 2011; 5
Raychaudhuri (ref_54) 2017; 162
Schaff (ref_77) 2020; 146
Nielsen (ref_42) 2010; 16
Asaoka (ref_9) 2019; 45
Yoshioka (ref_65) 2015; 22
Dowsett (ref_72) 2011; 103
Bianchini (ref_84) 2017; 19
ref_83
Magbanua (ref_36) 2021; 32
Bossuyt (ref_10) 2015; 26
Denkert (ref_60) 2017; 389
Lokman (ref_80) 2011; 4
Symmans (ref_11) 2007; 25
ref_45
ref_89
Liu (ref_50) 2019; 84
Harris (ref_85) 2016; 34
Ross (ref_24) 2012; 132
Marchat (ref_53) 2019; 41
Openshaw (ref_59) 2016; 16
Shi (ref_23) 2017; 28
Perou (ref_37) 2000; 406
ref_49
Fasching (ref_21) 2018; 36
Guo (ref_22) 2020; 52
ref_5
McDonald (ref_12) 2019; 11
Kaklamani (ref_27) 2015; 151
ref_7
Chang (ref_38) 2005; 7
Allred (ref_64) 1998; 11
References_xml – volume: 6
  start-page: e03241
  year: 2020
  ident: ref_81
  article-title: Annexin 2 Protein Expression Is Associated with Breast Cancer Subtypes in African American Women
  publication-title: Heliyon
  doi: 10.1016/j.heliyon.2020.e03241
  contributor:
    fullname: Beyene
– ident: ref_5
– volume: 22
  start-page: 185
  year: 2015
  ident: ref_65
  article-title: Prognostic Significance of Pathologic Complete Response and Ki67 Expression after Neoadjuvant Chemotherapy in Breast Cancer
  publication-title: Breast Cancer
  doi: 10.1007/s12282-013-0474-2
  contributor:
    fullname: Yoshioka
– volume: 170
  start-page: 559
  year: 2018
  ident: ref_88
  article-title: Response Rates and Pathologic Complete Response by Breast Cancer Molecular Subtype Following Neoadjuvant Chemotherapy
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-018-4801-3
  contributor:
    fullname: Haque
– volume: 19
  start-page: 16
  year: 2017
  ident: ref_84
  article-title: Biomarker Analysis of the NeoSphere Study: Pertuzumab, Trastuzumab, and Docetaxel versus Trastuzumab plus Docetaxel, Pertuzumab plus Trastuzumab, or Pertuzumab plus Docetaxel for the Neoadjuvant Treatment of HER2-Positive Breast Cancer
  publication-title: Breast Cancer Res.
  doi: 10.1186/s13058-017-0806-9
  contributor:
    fullname: Bianchini
– volume: 15
  start-page: 131
  year: 2018
  ident: ref_63
  article-title: Protein Biomarkers for Subtyping Breast Cancer and Implications for Future Research
  publication-title: Expert Rev. Proteom.
  doi: 10.1080/14789450.2018.1421071
  contributor:
    fullname: Mueller
– volume: 9
  start-page: 375
  year: 2008
  ident: ref_44
  article-title: Application of Serial Analysis of Gene Expression in Cancer Research
  publication-title: Curr. Pharm. Biotechnol.
  doi: 10.2174/138920108785915102
  contributor:
    fullname: Yamashita
– volume: 16
  start-page: 395
  year: 2013
  ident: ref_74
  article-title: Expression of Immunohistochemical Markers before and after Neoadjuvant Chemotherapy in Breast Carcinoma, and Their Use as Predictors of Response
  publication-title: J. Breast Cancer
  doi: 10.4048/jbc.2013.16.4.395
  contributor:
    fullname: Lee
– volume: 4
  start-page: 256
  year: 2015
  ident: ref_90
  article-title: Cancer Biomarker Discovery and Validation
  publication-title: Transl. Cancer Res.
  contributor:
    fullname: Goossens
– volume: 162
  start-page: 511
  year: 2017
  ident: ref_54
  article-title: MicroRNAs MiR-7 and MiR-340 Predict Response to Neoadjuvant Chemotherapy in Breast Cancer
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-017-4132-9
  contributor:
    fullname: Raychaudhuri
– volume: 72
  start-page: 2428
  year: 2012
  ident: ref_61
  article-title: Proteomic Portrait of Human Breast Cancer Progression Identifies Novel Prognostic Markers
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-11-3711
  contributor:
    fullname: Geiger
– volume: 80
  start-page: 1093
  year: 2020
  ident: ref_17
  article-title: Liquid Biopsy in Breast Cancer
  publication-title: Geburtshilfe Frauenheilkd
  doi: 10.1055/a-1124-7225
  contributor:
    fullname: Krawczyk
– ident: ref_51
  doi: 10.1186/s12916-018-1163-y
– ident: ref_83
  doi: 10.3390/cancers12082012
– volume: 32
  start-page: 229
  year: 2021
  ident: ref_36
  article-title: Circulating Tumor DNA in Neoadjuvant-Treated Breast Cancer Reflects Response and Survival
  publication-title: Ann. Oncol.
  doi: 10.1016/j.annonc.2020.11.007
  contributor:
    fullname: Magbanua
– volume: 41
  start-page: 3527
  year: 2019
  ident: ref_53
  article-title: MiR-145-5p Is Associated with Pathological Complete Response to Neoadjuvant Chemotherapy and Impairs Cell Proliferation by Targeting TGFβR2 in Breast Cancer
  publication-title: Oncol. Rep.
  contributor:
    fullname: Marchat
– volume: 84
  start-page: 1039
  year: 2019
  ident: ref_50
  article-title: Serum MicroRNA-21 Predicted Treatment Outcome and Survival in HER2-Positive Breast Cancer Patients Receiving Neoadjuvant Chemotherapy Combined with Trastuzumab
  publication-title: Cancer Chemother. Pharmacol.
  doi: 10.1007/s00280-019-03937-9
  contributor:
    fullname: Liu
– volume: 11
  start-page: eaax7392
  year: 2019
  ident: ref_12
  article-title: Personalized Circulating Tumor DNA Analysis to Detect Residual Disease after Neoadjuvant Therapy in Breast Cancer
  publication-title: Sci. Transl. Med.
  doi: 10.1126/scitranslmed.aax7392
  contributor:
    fullname: McDonald
– volume: 78
  start-page: 6001
  year: 2018
  ident: ref_62
  article-title: Clinical Proteomics of Breast Cancer Reveals a Novel Layer of Breast Cancer Classification
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-18-1079
  contributor:
    fullname: Yanovich
– volume: 228–229
  start-page: 159
  year: 2018
  ident: ref_35
  article-title: Analysis of Circulating Tumor DNA in Breast Cancer as a Diagnostic and Prognostic Biomarker
  publication-title: Cancer Genet.
  doi: 10.1016/j.cancergen.2018.02.002
  contributor:
    fullname: Rohanizadegan
– volume: 17
  start-page: 330
  year: 2011
  ident: ref_28
  article-title: Cancer Epigenetics Reaches Mainstream Oncology
  publication-title: Nat. Med.
  doi: 10.1038/nm.2305
  contributor:
    fullname: Esteller
– volume: 11
  start-page: 8623
  year: 2005
  ident: ref_39
  article-title: Tumor Gene Expression and Prognosis in Breast Cancer Patients with 10 or More Positive Lymph Nodes
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-05-0735
  contributor:
    fullname: Cobleigh
– volume: 375
  start-page: 717
  year: 2016
  ident: ref_40
  article-title: 70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer
  publication-title: N. Engl. J. Med.
  doi: 10.1056/NEJMoa1602253
  contributor:
    fullname: Cardoso
– volume: 52
  start-page: 689
  year: 2020
  ident: ref_22
  article-title: PIK3CA H1047R Mutation Associated with a Lower Pathological Complete Response Rate in Triple-Negative Breast Cancer Patients Treated with Anthracycline-Taxane–Based Neoadjuvant Chemotherapy
  publication-title: Cancer Res. Treat.
  doi: 10.4143/crt.2019.497
  contributor:
    fullname: Guo
– volume: 4
  start-page: 199
  year: 2011
  ident: ref_80
  article-title: The Role of Annexin A2 in Tumorigenesis and Cancer Progression
  publication-title: Cancer Microenviron.
  doi: 10.1007/s12307-011-0064-9
  contributor:
    fullname: Lokman
– volume: 5
  start-page: 66
  year: 2019
  ident: ref_2
  article-title: Breast Cancer
  publication-title: Nat. Rev. Dis. Primers
  doi: 10.1038/s41572-019-0111-2
  contributor:
    fullname: Harbeck
– volume: 45
  start-page: 2289
  year: 2019
  ident: ref_9
  article-title: Clinical and Pathological Predictors of Recurrence in Breast Cancer Patients Achieving Pathological Complete Response to Neoadjuvant Chemotherapy
  publication-title: Eur. J. Surg. Oncol.
  doi: 10.1016/j.ejso.2019.08.001
  contributor:
    fullname: Asaoka
– volume: 41
  start-page: 12
  year: 2021
  ident: ref_87
  article-title: The Way of the Future: Personalizing Treatment Plans Through Technology
  publication-title: Am. Soc. Clin. Oncol. Educ. Book
  doi: 10.1200/EDBK_320593
  contributor:
    fullname: Liefaard
– volume: 5
  start-page: 219
  year: 2004
  ident: ref_78
  article-title: The Annexins
  publication-title: Genome Biol.
  doi: 10.1186/gb-2004-5-4-219
  contributor:
    fullname: Moss
– volume: 389
  start-page: 2430
  year: 2017
  ident: ref_60
  article-title: Molecular Alterations in Triple-Negative Breast Cancer—the Road to New Treatment Strategies
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)32454-0
  contributor:
    fullname: Denkert
– volume: 11
  start-page: 155
  year: 1998
  ident: ref_64
  article-title: Prognostic and Predictive Factors in Breast Cancer by Immunohistochemical Analysis
  publication-title: Mod. Pathol.
  contributor:
    fullname: Allred
– ident: ref_89
  doi: 10.3390/ijms22020636
– volume: 25
  start-page: 3887
  year: 2019
  ident: ref_52
  article-title: Plasma MiRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-Positive Breast Cancer: Results from the NeoALTTO Trial
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-18-2507
  contributor:
    fullname: Cosimo
– volume: 2017
  start-page: e1750925
  year: 2017
  ident: ref_67
  article-title: PD-L1 Expression in TNBC: A Predictive Biomarker of Response to Neoadjuvant Chemotherapy?
  publication-title: BioMed Res. Int.
  doi: 10.1155/2017/1750925
  contributor:
    fullname: Cerbelli
– volume: 16
  start-page: 5222
  year: 2010
  ident: ref_42
  article-title: A Comparison of PAM50 Intrinsic Subtyping with Immunohistochemistry and Clinical Prognostic Factors in Tamoxifen-Treated Estrogen Receptor–Positive Breast Cancer
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-10-1282
  contributor:
    fullname: Nielsen
– volume: 34
  start-page: 1134
  year: 2016
  ident: ref_85
  article-title: Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2015.65.2289
  contributor:
    fullname: Harris
– volume: 26
  start-page: 1280
  year: 2015
  ident: ref_10
  article-title: Recommendations for Standardized Pathological Characterization of Residual Disease for Neoadjuvant Clinical Trials of Breast Cancer by the BIG-NABCG Collaboration
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdv161
  contributor:
    fullname: Bossuyt
– volume: 243
  start-page: 64
  year: 2006
  ident: ref_34
  article-title: Quantitative Analysis of Plasma Circulating DNA at Diagnosis and during Follow-up of Breast Cancer Patients
  publication-title: Cancer Lett.
  doi: 10.1016/j.canlet.2005.11.027
  contributor:
    fullname: Huang
– volume: 5
  start-page: 5
  year: 2011
  ident: ref_4
  article-title: Deconstructing the Molecular Portraits of Breast Cancer
  publication-title: Mol. Oncol.
  doi: 10.1016/j.molonc.2010.11.003
  contributor:
    fullname: Prat
– volume: 406
  start-page: 747
  year: 2000
  ident: ref_37
  article-title: Molecular Portraits of Human Breast Tumours
  publication-title: Nature
  doi: 10.1038/35021093
  contributor:
    fullname: Perou
– volume: 69
  start-page: 923
  year: 2012
  ident: ref_69
  article-title: Predictive Value of MGMT, HMLH1, HMSH2 and BRCA1 Protein Expression for Pathological Complete Response to Neoadjuvant Chemotherapy in Basal-like Breast Cancer Patients
  publication-title: Cancer Chemother. Pharmacol.
  doi: 10.1007/s00280-011-1777-7
  contributor:
    fullname: Nakai
– volume: 6
  start-page: 479
  year: 2016
  ident: ref_58
  article-title: Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy
  publication-title: Cancer Discov.
  doi: 10.1158/2159-8290.CD-15-1483
  contributor:
    fullname: Pantel
– volume: 93
  start-page: 1046
  year: 2005
  ident: ref_3
  article-title: Clinical Characteristics of Different Histologic Types of Breast Cancer
  publication-title: Br. J. Cancer
  doi: 10.1038/sj.bjc.6602787
  contributor:
    fullname: Li
– volume: 139
  start-page: 12
  year: 2016
  ident: ref_48
  article-title: Exploring Circulating Micro-RNA in the Neoadjuvant Treatment of Breast Cancer
  publication-title: Int. J. Cancer
  doi: 10.1002/ijc.29985
  contributor:
    fullname: Casey
– volume: 28
  start-page: 128
  year: 2017
  ident: ref_23
  article-title: Pathway Level Alterations Rather than Mutations in Single Genes Predict Response to HER2-Targeted Therapies in the Neo-ALTTO Trial
  publication-title: Ann. Oncol.
  doi: 10.1093/annonc/mdw434
  contributor:
    fullname: Shi
– volume: 26
  start-page: 366
  year: 2019
  ident: ref_46
  article-title: Oncotype DX® Recurrence Score as a Predictor of Response to Neoadjuvant Chemotherapy
  publication-title: Ann. Surg. Oncol.
  doi: 10.1245/s10434-018-07107-8
  contributor:
    fullname: Pease
– ident: ref_29
  doi: 10.1186/s12885-019-5403-0
– volume: 71
  start-page: 6195
  year: 2011
  ident: ref_32
  article-title: Genome-Wide Methylation Analysis Identifies Genes Specific to Breast Cancer Hormone Receptor Status and Risk of Recurrence
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-11-1630
  contributor:
    fullname: Fackler
– volume: 28
  start-page: 111
  year: 2020
  ident: ref_13
  article-title: Utility of Urinary CtDNA to Monitoring Minimal Residual Disease in Early Breast Cancer Patients
  publication-title: Cancer Biomark.
  doi: 10.3233/CBM-190523
  contributor:
    fullname: Guan
– volume: 16
  start-page: 861
  year: 2014
  ident: ref_26
  article-title: Chromosome 17 Centromere Duplication and Responsiveness to Anthracycline-Based Neoadjuvant Chemotherapy in Breast Cancer
  publication-title: Neoplasia
  doi: 10.1016/j.neo.2014.08.012
  contributor:
    fullname: Tibau
– volume: 84
  start-page: 861
  year: 2019
  ident: ref_68
  article-title: FKBP12 Is a Predictive Biomarker for Efficacy of Anthracycline-Based Chemotherapy in Breast Cancer
  publication-title: Cancer Chemother. Pharmacol.
  doi: 10.1007/s00280-019-03923-1
  contributor:
    fullname: Xing
– ident: ref_25
  doi: 10.1200/JCO.2010.31.2231
– volume: 47
  start-page: 2084
  year: 2011
  ident: ref_6
  article-title: Meta-Analysis Confirms Achieving Pathological Complete Response after Neoadjuvant Chemotherapy Predicts Favourable Prognosis for Breast Cancer Patients
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2011.06.014
  contributor:
    fullname: Kong
– volume: 25
  start-page: 4414
  year: 2007
  ident: ref_11
  article-title: Measurement of Residual Breast Cancer Burden to Predict Survival after Neoadjuvant Chemotherapy
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2007.10.6823
  contributor:
    fullname: Symmans
– volume: 16
  start-page: 751
  year: 2016
  ident: ref_59
  article-title: The Role of CtDNA Detection and the Potential of the Liquid Biopsy for Breast Cancer Monitoring
  publication-title: Expert Rev. Mol. Diagn.
  doi: 10.1080/14737159.2016.1184974
  contributor:
    fullname: Openshaw
– volume: 37
  start-page: 124
  year: 2018
  ident: ref_56
  article-title: Liquid Biopsy in Mice Bearing Colorectal Carcinoma Xenografts: Gateways Regulating the Levels of Circulating Tumor DNA (CtDNA) and MiRNA (CtmiRNA)
  publication-title: J. Exp. Clin. Cancer Res.
  doi: 10.1186/s13046-018-0788-1
  contributor:
    fullname: Gasparello
– volume: 45
  start-page: 1274
  year: 2009
  ident: ref_70
  article-title: Annexins in Human Breast Cancer: Possible Predictors of Pathological Response to Neoadjuvant Chemotherapy
  publication-title: Eur. J. Cancer
  doi: 10.1016/j.ejca.2008.12.026
  contributor:
    fullname: Chuthapisith
– volume: 67
  start-page: 88
  year: 2018
  ident: ref_18
  article-title: Metabolomics in Breast Cancer: A Decade in Review
  publication-title: Cancer Treat. Rev.
  doi: 10.1016/j.ctrv.2018.04.012
  contributor:
    fullname: McCartney
– volume: 9
  start-page: 3292
  year: 2018
  ident: ref_20
  article-title: The Therapeutic Significance of Mutational Signatures from DNA Repair Deficiency in Cancer
  publication-title: Nat. Commun.
  doi: 10.1038/s41467-018-05228-y
  contributor:
    fullname: Ma
– volume: 167
  start-page: 107
  year: 2018
  ident: ref_31
  article-title: Tumor and Serum DNA Methylation in Women Receiving Preoperative Chemotherapy with or without Vorinostat in TBCRC008
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-017-4503-2
  contributor:
    fullname: Connolly
– volume: 8
  start-page: 19039
  year: 2017
  ident: ref_30
  article-title: Pathological Complete Response of HER2-Positive Breast Cancer to Trastuzumab and Chemotherapy Can Be Predicted by HSD17B4 Methylation
  publication-title: Oncotarget
  doi: 10.18632/oncotarget.15118
  contributor:
    fullname: Fujii
– ident: ref_66
  doi: 10.1186/s12885-019-6353-2
– volume: 34
  start-page: 1271
  year: 2021
  ident: ref_14
  article-title: Predictors of Pathological Complete Response to Neoadjuvant Treatment and Changes to Post-Neoadjuvant HER2 Status in HER2-Positive Invasive Breast Cancer
  publication-title: Mod. Pathol.
  doi: 10.1038/s41379-021-00738-5
  contributor:
    fullname: Katayama
– volume: 384
  start-page: 164
  year: 2014
  ident: ref_82
  article-title: Pathological Complete Response and Long-Term Clinical Benefit in Breast Cancer: The CTNeoBC Pooled Analysis
  publication-title: Lancet
  doi: 10.1016/S0140-6736(13)62422-8
  contributor:
    fullname: Cortazar
– volume: 65
  start-page: 7065
  year: 2005
  ident: ref_47
  article-title: MicroRNA Gene Expression Deregulation in Human Breast Cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-05-1783
  contributor:
    fullname: Iorio
– volume: 17
  start-page: 6012
  year: 2011
  ident: ref_41
  article-title: A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk Factors
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-11-0926
  contributor:
    fullname: Filipits
– volume: 7
  start-page: 100
  year: 2005
  ident: ref_38
  article-title: The Promise of Microarrays in the Management and Treatment of Breast Cancer
  publication-title: Breast Cancer Res.
  doi: 10.1186/bcr1018
  contributor:
    fullname: Chang
– ident: ref_7
  doi: 10.1001/jamaoncol.2020.2535
– volume: 24
  start-page: R445
  year: 2014
  ident: ref_16
  article-title: Polymerase Stalling during Replication, Transcription and Translation
  publication-title: Curr. Biol.
  doi: 10.1016/j.cub.2014.03.060
  contributor:
    fullname: Edenberg
– ident: ref_45
  doi: 10.3390/cancers12051133
– ident: ref_75
  doi: 10.3390/ijms18020459
– volume: 88
  start-page: 406
  year: 2003
  ident: ref_73
  article-title: Breast Cancer Response to Neoadjuvant Chemotherapy: Predictive Markers and Relation with Outcome
  publication-title: Br. J. Cancer
  doi: 10.1038/sj.bjc.6600749
  contributor:
    fullname: Faneyte
– volume: 40
  start-page: 139
  year: 2014
  ident: ref_19
  article-title: Omic-Profiling in Breast Cancer Metastasis to Bone: Implications for Mechanisms, Biomarkers and Treatment
  publication-title: Cancer Treat. Rev.
  doi: 10.1016/j.ctrv.2013.07.006
  contributor:
    fullname: Wood
– volume: 132
  start-page: 781
  year: 2012
  ident: ref_24
  article-title: TP53 Genomics Predict Higher Clinical and Pathologic Tumor Response in Operable Early-Stage Breast Cancer Treated with Docetaxel-Capecitabine ± Trastuzumab
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-011-1412-7
  contributor:
    fullname: Ross
– volume: 2
  start-page: e197700
  year: 2019
  ident: ref_86
  article-title: Artificial Intelligence Algorithms to Assess Hormonal Status From Tissue Microarrays in Patients With Breast Cancer
  publication-title: JAMA Netw. Open
  doi: 10.1001/jamanetworkopen.2019.7700
  contributor:
    fullname: Shamai
– volume: 147
  start-page: 61
  year: 2014
  ident: ref_55
  article-title: Changes in Serum Levels of MiR-21, MiR-210, and MiR-373 in HER2-Positive Breast Cancer Patients Undergoing Neoadjuvant Therapy: A Translational Research Project within the Geparquinto Trial
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-014-3079-3
  contributor:
    fullname: Gade
– volume: 103
  start-page: 1656
  year: 2011
  ident: ref_72
  article-title: Assessment of Ki67 in Breast Cancer: Recommendations from the International Ki67 in Breast Cancer Working Group
  publication-title: J. Natl. Cancer Inst.
  doi: 10.1093/jnci/djr393
  contributor:
    fullname: Dowsett
– volume: 36
  start-page: 2281
  year: 2018
  ident: ref_21
  article-title: BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2017.77.2285
  contributor:
    fullname: Fasching
– volume: 74
  start-page: 2160
  year: 2014
  ident: ref_33
  article-title: Novel Methylated Biomarkers and a Robust Assay to Detect Circulating Tumor DNA in Metastatic Breast Cancer
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-13-3392
  contributor:
    fullname: Fackler
– volume: 30
  start-page: 1796
  year: 2012
  ident: ref_8
  article-title: Definition and Impact of Pathologic Complete Response on Prognosis After Neoadjuvant Chemotherapy in Various Intrinsic Breast Cancer Subtypes
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2011.38.8595
  contributor:
    fullname: Untch
– volume: 2019
  start-page: 8393769
  year: 2019
  ident: ref_57
  article-title: Identification of Cell-Free Circulating MicroRNAs for the Detection of Early Breast Cancer and Molecular Subtyping
  publication-title: J. Oncol.
  doi: 10.1155/2019/8393769
  contributor:
    fullname: Souza
– ident: ref_79
  doi: 10.3390/ijms20174197
– volume: 341
  start-page: 758
  year: 1989
  ident: ref_76
  article-title: A Receptor for the Immuno-Suppressant FK506 Is a Cis–Trans Peptidyl-Prolyl Isomerase
  publication-title: Nature
  doi: 10.1038/341758a0
  contributor:
    fullname: Harding
– volume: 68
  start-page: 394
  year: 2018
  ident: ref_1
  article-title: Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries
  publication-title: CA Cancer J. Clin.
  doi: 10.3322/caac.21492
  contributor:
    fullname: Bray
– ident: ref_49
  doi: 10.3390/ijms21041386
– volume: 11
  start-page: 5678
  year: 2005
  ident: ref_15
  article-title: Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
  publication-title: Clin. Cancer Res.
  doi: 10.1158/1078-0432.CCR-04-2421
  contributor:
    fullname: Rouzier
– volume: 104
  start-page: 1762
  year: 2011
  ident: ref_43
  article-title: Prognostic Utility of HOXB13:IL17BR and Molecular Grade Index in Early-Stage Breast Cancer Patients from the Stockholm Trial
  publication-title: Br. J. Cancer
  doi: 10.1038/bjc.2011.145
  contributor:
    fullname: Jerevall
– volume: 146
  start-page: 163
  year: 2020
  ident: ref_77
  article-title: Characterization of MGMT and EGFR Protein Expression in Glioblastoma and Association with Survival
  publication-title: J. Neurooncol.
  doi: 10.1007/s11060-019-03358-x
  contributor:
    fullname: Schaff
– volume: 151
  start-page: 629
  year: 2015
  ident: ref_27
  article-title: Phase II Neoadjuvant Clinical Trial of Carboplatin and Eribulin in Women with Triple Negative Early-Stage Breast Cancer (NCT01372579)
  publication-title: Breast Cancer Res. Treat.
  doi: 10.1007/s10549-015-3435-y
  contributor:
    fullname: Kaklamani
– volume: 11
  start-page: 174
  year: 2010
  ident: ref_71
  article-title: Ki67 in Breast Cancer: Prognostic and Predictive Potential
  publication-title: Lancet Oncol.
  doi: 10.1016/S1470-2045(09)70262-1
  contributor:
    fullname: Yerushalmi
SSID ssj0000331767
Score 2.3750043
SecondaryResourceType review_article
Snippet Neoadjuvant chemotherapy (NAC) is often used to treat locally advanced disease for tumor downstaging, thus improving the chances of breast-conserving surgery....
Simple SummaryBreast cancer is the most common cancer in women worldwide. Although many studies have aimed to understand the genetic basis of breast cancer,...
SourceID pubmedcentral
proquest
crossref
SourceType Open Access Repository
Aggregation Database
StartPage 5477
SubjectTerms Biomarkers
Breast cancer
Chemotherapy
DNA methylation
Genomics
Mutation
Patients
Precision medicine
Proteomics
Review
Transcriptomics
Tumors
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3da9swED-6FMpeyr7K0rVDgz7sxdSOZMvey1hKSxkkhLJC34xknVgGtdvYeeh_3ztbSZc97NUSFrqT7n73oTuAMx3b3MUmibQhNihlk8iYJItsnuqiyjypWXboz-bZ9a36eZfeBYdbG9IqNzKxF9SuqdhHfk4wnWwHUijF94fHiLtGcXQ1tNB4BfsTshTiEexPL-eLm62XJZakHzM91PSRZN-fV0zMVUtGGIEHrXfV0QvG3M2Q_EvlXL2Bw4AVxY-BuW9hD-t3cDAL0fD38DTb9LYV02Vzz4k2q1YsVjyhEwvTbSWb4GtPHEJxM-TEomi8mGNj3J81YelOcOGA8BjrSSxrMeVkdfrc74P_xe8m229iiCV8gNury18X11FopRBVssi7CA1bdtIRWnGkoyvauUFnrVMxejKRUSqScyrx3jvEisSkdal1mXQFaqm9PIJR3dT4EYREmyY-V6nvi5xPcpulmEiLcRpbYyZj-LqhaPkwVMwoydJg4pf_EH8MJxuKl-HqtOULo8fwZTtMh54jGabGZt3P0apQOs7HoHc4tV2Sy2bvjtTL33357Dzl57rJ8f8X_wSvJ5y-0qupExh1qzWeEv7o7OdwyJ4B6BvhIw
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3fa9swED7WDkpfyn60NG03NNjDXtzZkWzZg1LWsRAGKWUs0DcjWSea0tqt48Dy3-_OdtJl9GlPBluy0Z10933W6Q7gow5t6kITBdqQGpSyUWBMlAQ2jXVWJJ7cLP_Qn1wm46n6cR1fP5UD6gU4f5bacT2paX13-vtxeU4L_owZJ1H2zwXLp54TryI8oPUWvBwqoukcx9dj_dYsS3KVie7S-zzXbxd2JF2IP4SbTuoJeW7GTf7liEavYK9HkOJrp_LX8ALLN7Az6ffI38Jysqp4Ky5m1T2H39RzcVVzg0ZcmWZt7wQbA9Ibip9dpCyKyotLrIy7XRDCbgSnE-iPaC3FrBQXHMJOt9sh8bv4NOX8i-h2GPZhOvr-69s46AssBIXM0iZAw3xPOsIwjjx3QaM36Kx1KkRPxBmlIuunIu-9QyzIeFoXW5dIl6GW2ssD2C6rEg9BSLRx5FMV-zb1-TC1SYyRtBjGoTVmOIBPK4nmD10ejZz4B-sh_0cPAzhZSTxfzYecWBpRR8IT2QA-rB_TUuD9DVNitWjbaJUpHaYD0BuaWn-Sk2lvPilnN21S7TTmQ7zR0X_3PIbdIce7tH7tBLabeoHvCLA09n07Ef8Asqjw-A
  priority: 102
  providerName: Scholars Portal
Title Molecular Biomarkers Predict Pathological Complete Response of Neoadjuvant Chemotherapy in Breast Cancer Patients: Review
URI https://www.proquest.com/docview/2596012429
https://search.proquest.com/docview/2597494708
https://pubmed.ncbi.nlm.nih.gov/PMC8582511
Volume 13
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3da9swED-aDsZexj5Zti5osIe9uLEjybL3tpR2ZeAQygp5M5J1YimLXRLnof_9TrKdNXvciw2W_CHdSXc_63cngM8qNpmNdRIpTWIQwiSR1kkamUyqvEodmVn_Q79YpNe34sdKrk5ADrEwgbRfmfV5_XtzXq9_BW7l_aaaDjyx6bK4yKQPuEymIxiRgj6C6GH65WQSU9Wl8eEE6aeV77_tjnAX-QvKb7vH6UQ4IT42Rn89zGN-5CODc_UCnveeIvvWfdFLOMH6FTwt-rXw1_BQDDvbsvm62XiazXbHlltfoWVL3R7mNeYHPckH2U3HiEXWOLbARtu7PXnSLfNpA_pQrAe2rtncU9XpcmiSf5aPmtx9Zd1Kwhu4vbr8eXEd9RspRBXPszZC7XEdt-SrWLLQFbVeozXGihgdAWTkgmY5kTjnLGJFk6Sx0tiU2xwVV46_hdO6qfEdMI5GJi4T0oUU57PMpBITbjCWsdF6NoYvQ4-W912-jJJwhpdD-Y8cxnA29HjZD5xdSWiMICL5DfkYPh2KSeX9OoausdmHOkrkQsXZGNSRpA6v9Emzj0tIl0Ly7F533v_3nR_g2czzWoL9OoPTdrvHj-SYtGYCT-aXi-XNBEbfVwkdC5FNgnL-Aaz77CE
link.rule.ids 230,315,730,783,787,888,2228,21400,24330,27936,27937,33756,33757,43817,53804,53806,74630
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3Nb9MwFH-CTQIuaHyJwgAjceASLamdOOGC6LSpwFpV0ybtFtnxs-ikJaNJD_vveS9xO8qBa2zF8nv2-_bvAXzSsc1dbJJIG2KDUjaJjEmyyOapLqrMk5rlgP5snk0v1Y-r9CoE3NpQVrmRib2gdk3FMfIjMtPJdyCFUny9_R1x1yjOroYWGg9hn6GqyPnan5zMF-fbKEssST9mesD0keTfH1VMzFVLThgZD1rvqqN7G3O3QvIvlXN6AE-DrSi-Dcx9Bg-wfg6PZiEb_gLuZpvetmKybG640GbVisWKJ3RiYbqtZBN87YlDKM6HmlgUjRdzbIy7XpMt3QkGDgiPse7EshYTLlanz_0--F_8brL9IoZcwku4PD25OJ5GoZVCVMki7yI07NlJR9aKI0JVtHODzlqnYvTkIqNUJOdU4r13iBWJSetS6zLpCtRSe_kK9uqmxtcgJNo08blKfQ9yPs5tlmIiLcZpbI0Zj-DzhqLl7YCYUZKnwcQv_yH-CA43FC_D1WnLe0aP4ON2mA49ZzJMjc26n6NVoXScj0DvcGq7JMNm747Uy189fHae8nPd5M3_F_8Aj6cXs7Py7Pv851t4MuZSll5lHcJet1rjO7JFOvs-HLg_va3kHQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Lj9MwEB5BV1pxQTxFYQEjceASNamdOOGCKGy1PFpVK1baW2THY22RSJYmPey_ZyZxu5QD19iK5Rl7Hp5vZgDe6tjmLjZJpA2xQSmbRMYkWWTzVBdV5knN8oP-YpmdXaivl-llwD-1AVa5k4m9oHZNxW_kEzLTyXcghVJMfIBFrD7PP1z_jriDFEdaQzuNu3CkVSbjERzNTper8_2LSyxJV2Z6qO8jydefVEzYTUsOGRkSWh-qplt78xAt-Zf6mT-A-8FuFB8HRj-EO1g_guNFiIw_hpvFrs-tmK2bXwy62bRiteEJnViZbi_lBIsA4haK8wEfi6LxYomNcT-3ZFd3gosIhMSsG7GuxYyB6_S53wf_i3Mo2_diiCs8gYv56Y9PZ1FoqxBVssi7CA17edKR5eJIX1e0c4POWqdi9OQuo1Qk81TivXeIFYlM61LrMukK1FJ7-RRGdVPjMxASbZr4XKW-L3g-zW2WYiItxmlsjZmO4d2OouX1UD2jJK-DiV_-Q_wxnOwoXoZr1Ja3TB_Dm_0wXQCOapgam20_R6tC6Tgfgz7g1H5JLqF9OFKvr_pS2nnKqbvJ8_8v_hqO6ayV378sv72Ae1NGtfTa6wRG3WaLL8ks6eyrcN7-AOgV6Es
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Molecular+Biomarkers+Predict+Pathological+Complete+Response+of+Neoadjuvant+Chemotherapy+in+Breast+Cancer+Patients%3A+Review&rft.jtitle=Cancers&rft.au=de+Freitas%2C+Ana+Julia+Aguiar&rft.au=Causin%2C+Rhafaela+Lima&rft.au=Varuzza%2C+Muriele+Bertagna&rft.au=Hidalgo+Filho%2C+Cassio+Murilo+Trovo&rft.date=2021-10-31&rft.pub=MDPI&rft.eissn=2072-6694&rft.volume=13&rft.issue=21&rft_id=info:doi/10.3390%2Fcancers13215477&rft_id=info%3Apmid%2F34771640&rft.externalDBID=PMC8582511
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2072-6694&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2072-6694&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2072-6694&client=summon